BR112019004534A2 - análogo de amilina, método para a síntese e composição farmacêutica - Google Patents

análogo de amilina, método para a síntese e composição farmacêutica

Info

Publication number
BR112019004534A2
BR112019004534A2 BR112019004534A BR112019004534A BR112019004534A2 BR 112019004534 A2 BR112019004534 A2 BR 112019004534A2 BR 112019004534 A BR112019004534 A BR 112019004534A BR 112019004534 A BR112019004534 A BR 112019004534A BR 112019004534 A2 BR112019004534 A2 BR 112019004534A2
Authority
BR
Brazil
Prior art keywords
synthesis
pharmaceutical composition
amylin analog
disorders
analogs
Prior art date
Application number
BR112019004534A
Other languages
English (en)
Inventor
Heimriether Alexander
Wolfgang Hamprecht Dieter
FOSSATI Giacomo
Kofoed Munch Henrik
Mosolff Mathiesen Jesper
Skodborg Villadsen Jesper
Giehm Lise
Original Assignee
Boehringer Ingelheim Int
Zealand Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int, Zealand Pharma As filed Critical Boehringer Ingelheim Int
Publication of BR112019004534A2 publication Critical patent/BR112019004534A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Reproductive Health (AREA)

Abstract

a presente invenção se refere a análogos de amilina e a seu uso no tratamento ou prevenção de uma variedade de doenças, afecções ou distúrbios, que incluem obesidade, ingestão excessiva de alimentos e doenças metabólicas associadas tais como diabetes. os análogos têm boa estabilidade física e química, boa solubilidade, e uma duração longa de ação, e são bem adaptados para uso na forma de uma formulação líquida.
BR112019004534A 2016-09-09 2017-09-11 análogo de amilina, método para a síntese e composição farmacêutica BR112019004534A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16188024 2016-09-09
PCT/EP2017/072718 WO2018046719A1 (en) 2016-09-09 2017-09-11 Amylin analogues

Publications (1)

Publication Number Publication Date
BR112019004534A2 true BR112019004534A2 (pt) 2019-06-25

Family

ID=56990230

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019004534A BR112019004534A2 (pt) 2016-09-09 2017-09-11 análogo de amilina, método para a síntese e composição farmacêutica

Country Status (26)

Country Link
US (4) US10071140B2 (pt)
EP (2) EP3510044B1 (pt)
JP (1) JP7064103B2 (pt)
KR (1) KR102498393B1 (pt)
CN (1) CN109863168B (pt)
AR (1) AR109514A1 (pt)
AU (1) AU2017322277B2 (pt)
BR (1) BR112019004534A2 (pt)
CA (1) CA3035958A1 (pt)
CL (1) CL2019000575A1 (pt)
CO (1) CO2019002159A2 (pt)
DK (1) DK3510044T3 (pt)
EA (1) EA201990360A1 (pt)
ES (1) ES2901386T3 (pt)
IL (1) IL264864B2 (pt)
MA (1) MA46180A (pt)
MX (1) MX2019002599A (pt)
MY (1) MY197024A (pt)
PE (1) PE20190963A1 (pt)
PH (1) PH12019500474A1 (pt)
SA (1) SA519401239B1 (pt)
SG (1) SG11201901423XA (pt)
TW (1) TWI784968B (pt)
UA (1) UA123369C2 (pt)
WO (1) WO2018046719A1 (pt)
ZA (1) ZA201901253B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3271381B1 (en) 2015-03-18 2021-09-08 Zealand Pharma A/S Amylin analogues
US10071140B2 (en) 2016-09-09 2018-09-11 Zealand Pharma A/S Amylin analogues
AR116632A1 (es) 2018-10-11 2021-05-26 Intarcia Therapeutics Inc Polipéptidos análogos de la amilina humana y sus métodos de uso
WO2021094259A1 (en) 2019-11-11 2021-05-20 Boehringer Ingelheim International Gmbh Npy2 receptor agonists
BR112022025623A2 (pt) 2020-08-07 2023-03-07 Boehringer Ingelheim Int Agonistas solúveis de receptores de npy2
EP4144362A1 (en) 2021-09-06 2023-03-08 Adocia Compositions comprising short-acting hormones for treating or preventing obesity and pumps comprising said composition
WO2022248419A2 (en) 2021-05-22 2022-12-01 Adocia Compositions comprising short-acting hormones for treating or preventing obesity and pumps comprising said composition
EP4129324A1 (en) 2021-08-02 2023-02-08 Adocia Compositions comprising at least an amylin receptor agonist and a glp-1 receptor agonist
TW202346323A (zh) 2022-02-07 2023-12-01 英商梅迪繆思有限公司 具有改善的生物穩定性的ｇｌｐ—１及升糖素雙重激動肽
WO2023227133A1 (zh) * 2022-05-27 2023-11-30 杭州先为达生物科技股份有限公司 人胰淀素类似物、其衍生物及用途
WO2023232781A1 (en) 2022-05-30 2023-12-07 Zealand Pharma A/S Liquid formulations of amylin analogues
WO2024022465A1 (zh) * 2022-07-29 2024-02-01 杭州九源基因工程有限公司 一种人胰淀素多肽衍生物及其用途
WO2024061919A1 (en) 2022-09-19 2024-03-28 Zealand Pharma A/S Combination therapy

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5175146A (en) 1989-12-05 1992-12-29 Vical, Inc. Synthetic calcitonin peptides
US5234906A (en) 1991-01-10 1993-08-10 Amylin Pharmaceuticals, Inc. Hyperglycemic compositions
HU222249B1 (hu) 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
WO1992015317A1 (en) 1991-03-08 1992-09-17 Amylin Pharmaceuticals, Inc. Synthetic preparation of amylin and amylin analogues
SK88793A3 (en) 1991-11-19 1994-12-07 Amylin Pharmaceuticals Inc Amylin agonising peptides and their using
SG98356A1 (en) 1993-09-07 2003-09-19 Amylin Pharmaceuticals Inc Methods for regulating gastrointestinal motility
WO1998008871A1 (en) 1996-08-30 1998-03-05 Novo Nordisk A/S Glp-1 derivatives
WO1998011125A1 (en) 1996-09-09 1998-03-19 Zealand Pharmaceuticals A/S Improved solid-phase peptide synthesis and agent for use in such synthesis
US5677279A (en) 1996-12-16 1997-10-14 Amylin Pharmaceuticals, Inc. Methods and compositions for treating pain with amylin or agonists thereof
US7101853B2 (en) 1997-05-06 2006-09-05 Amylin Pharmaceuticals, Inc. Method for treating or preventing gastritis using amylin or amylin agonists
CA2206028C (en) 1997-06-04 2006-10-03 Frantisek Ziak Fitness-balance board
US7910548B2 (en) 1997-06-06 2011-03-22 Amylin Pharmaceuticals, Inc. Methods for treating obesity
WO1999034764A2 (en) * 1998-01-09 1999-07-15 Amylin Pharmaceuticals, Inc. Amylin agonist pharmaceutical compositions containing insulin
US6451987B1 (en) 1999-03-15 2002-09-17 Novo Nordisk A/S Ion exchange chromatography of proteins and peptides
DE60040333D1 (de) 1999-03-17 2008-11-06 Novo Nordisk As Verfahren zur acylierung von peptiden und proteinen
WO2005000222A2 (en) 2003-05-30 2005-01-06 Amylin Pharmaceuticals, Inc. Novel methods and compositions for enhanced transmucosal delivery of peptides and proteins
BRPI0507623A (pt) * 2004-02-11 2007-07-03 Amylin Pharmaceuticals Inc peptìdeos da famìlia da amilina e métodos para prepará-los e empregá-los
EP2417980A1 (en) 2004-02-11 2012-02-15 Amylin Pharmaceuticals Inc. Hybrid polypeptides with selectable properties
DE102004051014A1 (de) 2004-10-20 2006-04-27 Rwth Aachen Chemisch modifizierte Peptidanaloga
US20090286723A1 (en) 2005-02-11 2009-11-19 Amylin Pharmaceuticals, Inc. Hybrid Polypeptides with Selectable Properties
WO2007104789A2 (en) 2006-03-15 2007-09-20 Novo Nordisk A/S Amylin derivatives
CN101790538B (zh) 2007-02-15 2014-07-30 印第安纳大学研究与科技公司 胰高血糖素/glp-1受体共激动剂
US7994122B2 (en) 2007-06-15 2011-08-09 Zealand Pharma A/S Glucagon analogues
EP2036923A1 (en) 2007-09-11 2009-03-18 Novo Nordisk A/S Improved derivates of amylin
EP2036539A1 (en) 2007-09-11 2009-03-18 Novo Nordisk A/S Stable formulations of amylin and its analogues
EP2340261B1 (en) 2008-10-21 2017-12-20 Novo Nordisk A/S Amylin derivatives
CA2747155A1 (en) 2008-12-15 2010-06-24 Zealand Pharma A/S Glucagon analogues
JP5635530B2 (ja) 2008-12-15 2014-12-03 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
JP5635532B2 (ja) 2008-12-15 2014-12-03 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
MA32970B1 (fr) 2008-12-15 2012-01-02 Zealand Pharma As Analogues du glucagon
WO2010107874A2 (en) 2009-03-17 2010-09-23 Amylin Pharmaceuticals, Inc. Methods for affecting body composition using amylin agonists
SG177609A1 (en) 2009-07-13 2012-02-28 Zealand Pharma As Acylated glucagon analogues
JP5850848B2 (ja) 2009-11-25 2016-02-03 ノヴォ ノルディスク アー／エス ポリペプチドの製造方法
AR081975A1 (es) 2010-06-23 2012-10-31 Zealand Pharma As Analogos de glucagon
US9169310B2 (en) 2010-06-24 2015-10-27 Zealand Pharma A/S Glucagon analogues
US8722849B2 (en) 2011-06-10 2014-05-13 Novo Nordisk A/S Polypeptides
BR112014015681A2 (pt) 2011-12-23 2019-09-24 Boehringer Ingelheim Int análogos de glucagon
EP2838914B1 (en) 2012-04-19 2017-06-14 Novo Nordisk A/S Human amylin analogues
US8575091B1 (en) 2012-04-19 2013-11-05 Novo Nordisk A/S Amylin analogues and pharmaceutical compositions thereof
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
BR102013017626A2 (pt) 2013-06-14 2015-02-10 Univ Rio De Janeiro Bioconjugados não aglomerantes de amilinomiméticos com polietilenoglicol, uso de bioconjugados não aglomerantes de amilinomiméticos com polietilenoglicol, composições farmacêuticas de baixa toxicidade, adjuvante para a prevenção ou tratamento das doenças, medicamento, método de tratamento ou prevenção de doenças.
AR097701A1 (es) * 2013-09-19 2016-04-13 Zealand Pharma As Análogos de amilina
JP2016208556A (ja) 2013-10-03 2016-12-08 三菱電機株式会社 デマンド予測装置及びデマンド予測方法
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
TWI666220B (zh) 2013-10-17 2019-07-21 丹麥商西蘭製藥公司 醯化升糖素類似物
AR099936A1 (es) 2014-04-04 2016-08-31 Sanofi Sa Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados
DK3137494T3 (da) 2014-05-02 2021-10-04 Univ New York State Res Found Isletamyloidpolypeptider med forbedret opløselighed
JP6728141B2 (ja) 2014-09-04 2020-07-22 ノヴォ ノルディスク アー／エス 新規のアミリン及びカルシトニン受容体アゴニスト
MA41202A (fr) 2014-12-18 2017-10-24 Genzyme Corp Copolymères polydiallymine réticulé pour le traitement du diabète de type 2
EP3271381B1 (en) * 2015-03-18 2021-09-08 Zealand Pharma A/S Amylin analogues
US10071140B2 (en) 2016-09-09 2018-09-11 Zealand Pharma A/S Amylin analogues
US11028137B2 (en) 2017-02-01 2021-06-08 The Research Foundation For The State University Of New York Mutant islet amyloid polypeptides with improved solubility and methods for using the same

Also Published As

Publication number Publication date
IL264864A (pt) 2019-04-30
TWI784968B (zh) 2022-12-01
US12083164B2 (en) 2024-09-10
US10071140B2 (en) 2018-09-11
KR102498393B1 (ko) 2023-02-13
SA519401239B1 (ar) 2023-07-09
MA46180A (fr) 2021-03-24
MX2019002599A (es) 2019-09-18
PH12019500474A1 (en) 2019-08-05
ZA201901253B (en) 2022-10-26
IL264864B1 (en) 2023-06-01
KR20190045333A (ko) 2019-05-02
SG11201901423XA (en) 2019-03-28
CO2019002159A2 (es) 2019-07-31
EP3510044B1 (en) 2021-11-24
IL264864B2 (en) 2023-10-01
CL2019000575A1 (es) 2019-05-10
PE20190963A1 (es) 2019-07-08
EP4074729A1 (en) 2022-10-19
EP3510044A1 (en) 2019-07-17
AU2017322277B2 (en) 2021-11-11
TW201811818A (zh) 2018-04-01
DK3510044T3 (da) 2021-12-13
WO2018046719A1 (en) 2018-03-15
US11382956B2 (en) 2022-07-12
UA123369C2 (uk) 2021-03-24
AU2017322277A1 (en) 2019-03-28
US20200188485A1 (en) 2020-06-18
JP2019534248A (ja) 2019-11-28
CN109863168B (zh) 2023-04-18
CN109863168A (zh) 2019-06-07
EA201990360A1 (ru) 2019-09-30
MY197024A (en) 2023-05-22
JP7064103B2 (ja) 2022-05-10
US20180071366A1 (en) 2018-03-15
CA3035958A1 (en) 2018-03-15
AR109514A1 (es) 2018-12-19
US20190134159A1 (en) 2019-05-09
US20210346468A1 (en) 2021-11-11
ES2901386T3 (es) 2022-03-22

Similar Documents

Publication Publication Date Title
BR112019004534A2 (pt) análogo de amilina, método para a síntese e composição farmacêutica
BR112017019378A2 (pt) análogos de amilina
ECSP19010079A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
CO2017011851A2 (es) Compuestos novedosos
BR112015014372A8 (pt) inibidores de autotaxina, seus usos, e composição e combinação farmacêuticas".
GT201300243A (es) Derivados de ácido 3-fenilpropiónico ramificados y su uso
CU20190101A7 (es) Imidazopirimidinas diazabicíclicas sustituidas
UY32094A (es) Derivados heterocíclicos, procesos para su preparación, medicamentos que comprenden dichos compuestos y su uso.
AR099569A1 (es) Derivados de insulina y los usos médicos de estos
BR112013017314A2 (pt) composições compreendendo inibidores de cotransportadores 1 e 2 de sódio-glicose e métodos de usos
EA201890449A1 (ru) Фумагиллиновые гетероциклические соединения и способы их получения и применения
CO7350641A2 (es) Compuestos de 2-fenil-5-heterociclil-tetrahidro-2h-piran-3-amina para uso en el tratamiento de diabetes y sus trastornos asociados
BR112015017251A8 (pt) composições farmacêuticas compreendendo doadores de nitroxil, misturas e usos das referidas composições farmacêuticas
BR112015019412A8 (pt) inibidores de bace1, seus usos, e composição farmacêutica
BR112017000898A2 (pt) oritavancina de alta pureza e método de produção da mesma
BR112017022757A2 (pt) derivados do pirazol úteis como inibidores da proteína ativadora da 5-lipoxigenase (flap)
BR112014031798A2 (pt) compostos de heteroaril e métodos de uso destes
BR112017020053A2 (pt) novo composto heterocíclico, método para a preparação do mesmo e composição farmacêutica compreendendo o mesmo
BR112017012906A2 (pt) composição contendo extrato misturado de amora e casca de poria cocos para a prevenção, melhora ou o tratamento de distúrbios neurodegenerativos
UY37622A (es) Derivados de pirazol como inhibidores de bromodominio de la familia bet y su uso en aplicaciones terapéuticas
CO2020002500A2 (es) Análogos de insulina acilados novedosos y usos de estos
CL2017002229A1 (es) Inhibidores de bace1.
BR112014018226A8 (pt) Derivados de pirimidooxazocina como inibidores de mtor
BR112016021835A8 (pt) análogo cíclico da apelina de fórmula geral x1-x2-x3-x4-x5-x6-x7-x8-x9-x10-x11-x12-x13-x14, composição farmacêutica, e método para proporcionar um análogo da apelina
BR112017003227A2 (pt) composto, composição farmacêutica e uso de um composto

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B25A Requested transfer of rights approved

Owner name: ZEALAND PHARMA A/S (DK)

B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]